

Tennessee State-Subdivision Opioid Abatement Agreement: Summary of 2025 Amendment 7

As with prior settlements, Tennessee local governments are being asked to amend the Tennessee State-Subdivision Opioid Abatement Agreement to have the Agreement apply to the new settlements with the Secondary Opioid Manufacturers. The proposed amendment is summarized below. The participation packet for the Secondary Opioid Manufacturer settlements being sent to counties and qualifying municipalities by the national settlement implementation administrator will also include a form to approve the amendment. This process for amending the State-Subdivision Agreement is the same as it was for prior amendments.

The amendment applying the State-Subdivision Agreement to the Secondary Opioid Manufacturer settlements is Amendment 7. Amendments 1-5, were approved in 2023 and 2024. Amendment 6, which applies the State-Subdivision Agreement to the settlements with Purdue Pharma and the Sackler family, is included in the settlement packet for the Purdue/Sackler settlement. A copy of the State-Subdivision Agreement with attached amendments 1-5 and information about Amendment 6 can be found on the Attorney General opioid settlement webpage: [Opioid Settlements \(tn.gov\)](https://opiodsettlements.tn.gov).

Summary of Amendment 7

This amendment applies the terms of the State-Subdivision Agreement to the new settlements with Secondary Opioid Manufacturers: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. This amendment ensures the structure and procedures that apply to prior opioid settlements with the three national pharmaceutical distributors, pharmacy chains, and manufacturers will be the same for the new settlements. For example, the formula for using overdose and other data to allocate funds among the counties would be the same for the new agreements as with the existing ones.

Following Page: Text of Amendment

On the next page is the text of the amendment, set out as it should appear in the settlement packets from the national administrator.

Tennessee State-Subdivision Opioid Abatement Agreement – 2025 Amendments

The Tennessee State-Subdivision Opioid Abatement Agreement, previously amended in 2023 and 2024, is further amended as follows:

Amendment 7:

Pursuant to Section IV.A, this Agreement shall apply to the following Statewide Opioid Settlement Agreements, should they become effective:

- A. Alvogen Settlement Agreement
- B. Amneal Settlement Agreement
- C. Apotex Settlement Agreement
- D. Hikma Settlement Agreement
- E. Indivior Settlement Agreement
- F. Mylan Settlement Agreement
- G. Sun Settlement Agreement
- H. Zydus Settlement Agreement

Note on adoption of amendment:

Amendment 7 shall be effective if approved as set forth in Section IV.B.2 of the Agreement.